Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Freenome has raised $240.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Freenome's investors include Andreessen Horowitz, RA Capital Management, Founders Fund, Cormorant Asset Management, Novartis.
Freenome is headquartered in South San Francisco, United States.
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Freenome is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Freenome — Funding & Investors." VCBacked, July 20, 2026, https://www.vcbacked.co/company/freenome. Accessed October 16, 2026.
VCBacked. (2026). Freenome — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/freenome
{{cite web |title=Freenome — Funding & Investors |url=https://www.vcbacked.co/company/freenome |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated